A second-generation CB1R antagonist (TM-38837) produced by 7TM Pharma has entered clinical trials for the treatment of obesity and metabolic disorders (Chorvat et al., 2012; Klumpers et al., 2013; Knani et al., 2016; Lu et al., 2016). This evidence concerns the gene CNR1 and metabolic disease.